Other studies have also shown that combinations of panobinostat with an EGFR inhibitor suppressed claudin-low (CL) TNBC cell proliferation, proposing class I HDACs as therapeutic targets for breast cancer patients with TNBC [40]. Here, EGFR is linked to breast cancer.